Addressing the challenges of affordable wound care access and delivery is crucial for individuals with chronic wounds. Globally, more than 40 million people grapple with chronic wounds, contributing to an annual economic burden exceeding €100 billion. Approximately 1-2% of the populations in developed countries will encounter chronic wounds in their lifetime, significantly impacting their quality of life. Existing treatment options fall short of meeting these needs. In response, SolasCure is in the process of developing Aurase Wound Gel, an investigational product. This hydrogel incorporates a highly-specific enzyme derived from and cloned from medical maggots. The medical application of Aurase Wound Gel aims to enhance wound cleaning, a prerequisite for healing, thereby fostering improved patient outcomes and reducing healthcare costs. With support from EIC, SolasCure aims to conduct Clinical Phase 2b trials and develop a dry formulation of Aurase Wound Gel, along with its optimization.